Immune monitoring plays an important role in detecting and characterising cellular immune responses at preclinical and clinical stages, and it is essential for the development and clinical application of TCR-T cell-based therapies. The identification and measurement of specific biomarkers provide insight into both the mechanism of action of the TCR-T drug product and the patient’s immune response throughout treatment. Medigene’s immune monitoring platform guarantees high-quality reagents, assays and data at every development step, from early research to patient assessment in clinical studies. Preclinical immune assessment and bioinformatics play an essential role in developing innovative immunotherapies, from the very early stages of discovery until the final approval of new treatments.
Clinical Development Abstracts
First-in-Human Study of MDG1011, a TCR-T Cell Therapy directed against HLA-A*02:01-Restricted PRAME, for High-Risk Myeloid and Lymphoid Neoplasms (CD-TCR-001) Simone Thomas, Martin Wermke, Vladan Vucinic, Eva Wagner-Drouet, Andreas
Mackensen, Robert Zeiser, Gesine Bug, Michael Schmitt, Petra U. Prinz, Dolores J. Schendel, Kai Pinkernell, René Goedkoop